Caris Life Sciences (CAI) Capital Expenditures (2024 - 2026)

Caris Life Sciences' Capital Expenditures history runs 3 years deep, the most recent figure standing at $10.3 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 284.6% year-over-year to $10.3 million; the TTM figure through Mar 2026 stood at $23.9 million (changed N/A YoY), while the FY2025 annual figure was $16.3 million, up 692.4% from the prior year.
• Capital Expenditures was $10.3 million for Q1 2026 at Caris Life Sciences, up from $5.1 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $10.3 million in Q1 2026 to a low of -$4.1 million in Q4 2024.
• Historically, Capital Expenditures has averaged $3.5 million across 3 years, with a median of $2.7 million in 2025.
• Biggest YoY gain for Capital Expenditures was 288.13% in 2025; the steepest drop was 224.09% in 2025.
• A 3-year view of Capital Expenditures shows it stood at -$4.1 million in 2024, then soared by 224.09% to $5.1 million in 2025, then jumped by 103.18% to $10.3 million in 2026.
• The last three Capital Expenditures figures came in at $10.3 million (Q1 2026), $5.1 million (Q4 2025), and $7.1 million (Q3 2025), per Business Quant data.